Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

galunisertib (LY2157299)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Eli Lilly

Drug class:

Phosphotransferase inhibitor, TGF-β1 inhibitor

Related drugs:

AFP elevation	Hepatocellular Cancer	AFP elevation	Hepatocellular Cancer	sorafenib + LY2157299 Sensitive: C2 – Inclusion Criteria sorafenib + LY2157299 Sensitive : C2	sorafenib + LY2157299 Sensitive: C2 – Inclusion Criteria sorafenib + LY2157299 Sensitive : C2
TGFB1 elevation	Hepatocellular Cancer	TGFB1 elevation	Hepatocellular Cancer	sorafenib + LY2157299 Sensitive: C3 – Early Trials sorafenib + LY2157299 Sensitive : C3	sorafenib + LY2157299 Sensitive: C3 – Early Trials sorafenib + LY2157299 Sensitive : C3
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	nivolumab + LY2157299 Sensitive: C4 – Case Studies nivolumab + LY2157299 Sensitive : C4	nivolumab + LY2157299 Sensitive: C4 – Case Studies nivolumab + LY2157299 Sensitive : C4